


PHARMACEUTICAL 2018

Axsome Therapeutics Inc. Rank 251 of 349





PHARMACEUTICAL 2018

Axsome Therapeutics Inc. Rank 251 of 349

The relative strengths and weaknesses of Axsome Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Axsome Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 117% points. The greatest weakness of Axsome Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 175% points.

The company's Economic Capital Ratio, given in the ranking table, is -364%, being 87% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	35,300
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,175
Liabilities, Non-Current	6,663
Other Assets	188
Other Compr. Net Income	0
Other Expenses	646
Other Liabilities	0
Other Net Income	-1,133
Property and Equipment	68
Research and Development	19,958
Revenues	0
Selling, General and Administrative Expense	7,207

Output Variable	Value in 1000 USD
Assets	35,556
Liabilities	18,838
Expenses	27,810
Stockholders Equity	16,717
Net Income	-28,943
Comprehensive Net Income	-28,943
Economic Capital Ratio	-364%